96 Tests PN: B111458
Components:
45x Ab-conjugated beads (S4P12 - human sTRAIL Ab-bead). PN: B111458A. One vial containing 100 µL of anti-human sTRAIL conjugated to AimPlex Bead S4P12.
25x Biotin-detection Ab (human sTRAIL Biotin-dAb). PN: B111458B. One vial containing 100 µL of biotinylated anti-human sTRAIL.
Lyophilized Standard Mix-Human Group 10, Panel B, 7-Plex. PN: HG1007B. One vial containing lyophilized recombinant Lymphotactin, MIA, Midkine, NOV, NRG1-beta1, sTACI, and sTRAIL. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human Human TNFSF10/sCD253/sTRAIL. Can be multiplexed with other analytes in Human Group 10. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Assay Specifications:
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 10 pg/mL
Quantitation range:
LLOQ: < 20 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 10: Negligible
Sample volume: 15 µL/test
Description:
TRAIL (TNF-related apoptosis-inducing ligand), is a cytokine functioning as a ligand that induces the process of cell death called apoptosis. TRAIL has also been designated CD253 and Tumor Necrosis Factor (Ligand) SuperFamily, Member 10 (TNFSF10). TRAIL is produced and secreted by most normal tissue cells. It causes apoptosis primarily in tumor cells by binding to certain death receptors. Diseases associated with TNFSF10 include adult medulloblastoma and malignant glioma.
References:
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA (December 1995). "Identification and characterization of a new member of the TNF family that induces apoptosis". Immunity 3 (6): 673–82. doi:10.1016/1074-7613(95)90057-8. PMID 8777713.
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (May 1996). "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family". J. Biol. Chem. 271 (22): 12687–90. doi:10.1074/jbc.271.22.12687. PMID 8663110.
Cormier Z (February 2013). "Small-molecule drug drives cancer cells to suicide". Nature 494. doi:10.1038/nature.2013.12385.
Song JJ, Lee YJ (May 2008). "Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily". Cell. Signal. 20 (5): 892–906. doi:10.1016/j.cellsig.2008.01.001. PMC 2483832. PMID 18276109.